1 to 10 of 11 literature results

• Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.

  BACKGROUND & AIMS: Ribavirin (RBV) combined with either pegylated interferon (PegIFN) alpha2a or PegIFNalpha2b is the standard of care for chronic hep…

  Authors: Maria Grazia Rumi, Alessio Aghemo, Gian Maria Prati, Roberta D'Ambrosio, Maria Francesca Donato, Roberta Soffredini, Ersilio Del Ninno, Antonio Russo, Massimo Colombo

  Source: Gastroenterology. 2010 Jan

  View Full Text

• The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin.

  BACKGROUND: Interferon (IFN) combined with ribavirin (RBV) is an effective therapy for hepatitis C virus (HCV)-infected patients. Those who are coinfe…

  Authors: Mauro Viganò, Alessio Aghemo, Massimo Iavarone, Maria Grazia Rumi, Francesca Agnelli, Pietro Lampertico, Maria Francesca Donato, Massimo Colombo

  Source: Antiviral therapy. 2009

  View Full Text

• The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype.

  BACKGROUND: Failure of anti-hepatitis C therapy encompasses both primary non-response and post-treatment relapse. Treatment failure to pegylated inter…

  Authors: Alessio Aghemo, Maria Grazia Rumi, Sara Monico, Gian Maria Prati, Roberta D'Ambrosio, Maria Francesca Donato, Massimo Colombo

  Source: Antiviral therapy. 2009

  View Full Text

• Prevention of hepatocellular carcinoma.

  Prevention is the only realistic approach for reducing mortality rates associated with hepatocellular carcinoma (HCC) worldwide. Vaccination against h…

  Authors: Massimo Colombo, Maria Francesca Donato

  Source: Seminars in liver disease. 2005

  View Full Text

• Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease.

  OBJECTIVE: Transient elastography (TE) is gaining popularity as a non-invasive method for predicting liver fibrosis, but intraobserver and interobserv…

  Authors: Mirella Fraquelli, Cristina Rigamonti, Giovanni Casazza, Dario Conte, Maria Francesca Donato, Guido Ronchi, Massimo Colombo

  Source: Gut. 2007 Jul

  View Full Text

• A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C.

  BACKGROUND/AIMS: We performed a randomized trial on pegylated interferon alfa-2a (Peg-IFNalpha) monotherapy vs Peg-IFNalpha and ribavirin in non-cirrh…

  Authors: Mario Angelico, Alessandra Petrolati, Raffaella Lionetti, Ilaria Lenci, Patrizia Burra, Maria Francesca Donato, Manuela Merli, Mario Strazzabosco, Giuseppe Tisone

  Source: Journal of hepatology. 2007 Jun

  View Full Text

• The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies.

  BACKGROUND: Antibodies to liver-kidney microsome type 1 (anti-LKM-1), which are a marker of autoimmune hepatitis, are found in a minority of patients …

  Authors: Valentina Monti, Alessio Aghemo, Maria Grazia Rumi, Maria Francesca Donato, Ersilio Del Ninno, Massimo Colombo

  Source: Antiviral therapy. 2005

  View Full Text

• The clinical and pathogenetic significance of estrogen receptor-beta expression in chronic liver diseases and liver carcinoma.

  BACKGROUND: Estrogen receptor-alpha (ERalpha) is variably expressed in hepatocellular carcinoma (HCC) and is believed to be correlated with prognosis …

  Authors: Massimo Iavarone, Pietro Lampertico, Chiara Seletti, Maria Francesca Donato, Guido Ronchi, Ersilio del Ninno, Massimo Colombo

  Source: Cancer. 2003 Aug 1

  View Full Text

• Might rapid virological response be used as a stopping rule in liver transplant recipients treated with pegylated interferon plus ribavirin?

  Authors: Maria Francesca Donato, Francesca Agnelli, Cristina Rigamonti, Eliana Arosio, Massimo Colombo

  Source: Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2008 Sep

  View Full Text

• Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.

  To assess whether extended treatment with interferon improves the outcome of hepatitis B e antigen (HBeAg)-negative chronic hepatitis B, 101 consecuti…

  Authors: Pietro Lampertico, Ersilio Del Ninno, Mauro Viganò, Raffaella Romeo, Maria Francesca Donato, Erwin Sablon, Alberto Morabito, Massimo Colombo

  Source: Hepatology (Baltimore, Md.). 2003 Apr

  View Full Text